Moderna, Merck begin phase 3 trial on mRNA melanoma combo treatment
Nasekom

Moderna (NASDAQ:MRNA) and Merck (MRK) have begun a phase 3 trial testing a combination of the former's neoantigen therapy V940 (mRNA-4157) and the latter's Keytruda (pembrolizumab) for resected high-risk melanoma.
The randomized, double-blind, placebo- and active-comparator-controlled study plans to enroll ~1.1K patients across the world. The primary endpoint of the study is recurrence-free survival, and secondary endpoints include distant metastasis-free survival, overall survival, and safety.

Both the US FDA and European Medicines Agency have granted Breakthrough Therapy designation and the Priority Medicines scheme, respectively, for the combination.
The companies added they plan on expanding the development program to include non-small cell lung cancer.

More on Moderna/Merck cancer treatment

Moderna/ Merck cancer shot with Keytruda cut melanoma spread
Moderna, Merck post detailed Phase 2 data for mRNA cancer shot in melanoma